Urinary Tumor Markers for Bladder Cancer
Customize your policy alerts
Sign up for avalon_healthcare_solutions Policy AHS - G2125 - Urinary Tumor Markers for Bladder Cancer alerts
Get alerted when Policy AHS - G2125 - Urinary Tumor Markers for Bladder Cancer changes without checking for updates manually.
Monitor payer policy activity
Defines coverage stance and clinical indications/limitations for urinary tumor marker tests (e.g., BTA, NMP22, UroVysion, ImmunoCyt, and other urinary biomarker assays) for diagnosis and surveillance of bladder cancer for Avalon Healthcare Solutions members.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.